Tb, I do not understand your reaction very well at all because I...

Tb, I do not understand your reaction very well at all because I think this update is rather a positive than negative thing. The problem with both AD and HD has been the difficulty to demonstrate efficacy because the tools what there are, are not very developed and it was difficult and expensive to find cases for both studies and so we had to wait the results for long time.
Now Prana will do studies in acute indications. This kind of thinking was impossible still 1/2 years ago, the only possibility earlier was to find a bit smarter tools, and collect more patients for longer time.
Now suddenly we are dealing with mitochondria diseases as cardiomyopathy etc. and in these problems we have clear tools to evaluate if the disease is getting better or not. In the late stage HD patients as AD patients get often cardiomyopathy ( as a new symptom of the same mitochondria disease) . Let us say we can give some 500mg PBT2 for 4 weeks to this kind of HD patient. If the heart function results are improving it will be seen immediately in the follow-up and everybody understands that the heart works better . After this kind of quick testing and getting positive results PBT2 could get to the market much sooner than earlier. We do not need to treat patient for 1-2 years, may be 4 weeks is enough.
So the new " acute indication " studies are really a big help to Prana and us investors. And the potential market is perhaps at least some 10 times bigger than that of AD.
But we need to get started to see if these MPACs have any value in these acute indications. But if they have then also HD and Ad patients will be helped.